Current Report Filing (8-k)
December 15 2022 - 4:10PM
Edgar (US Regulatory)
0001760542
false
0001760542
2022-12-09
2022-12-09
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): December 9, 2022
HOOKIPA PHARMA INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-38869 |
|
81-5395687 |
(State
or other jurisdiction of
incorporation) |
|
(Commission
File Number) |
|
(I.R.S.
Employer
Identification No.) |
350
Fifth Avenue, 72nd Floor
Suite 7240 |
|
|
New York, New York |
|
10018 |
(Address
of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: +43 1 890 63 60
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class |
Trading Symbol(s) |
Name of each
exchange on which
registered |
Common stock, $0.0001 par value per share |
HOOK |
The Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 9, 2022, the Board of Directors (the “Board”)
of HOOKIPA Pharma Inc. (the Company”) appointed Malte Peters, M.D. as a director of the Board, effective January 1, 2023. Dr. Peters
will serve as a Class II director, to serve until the Company’s annual meeting of stockholders in 2024.
Dr. Peters has served as Chief Research and Development Officer of
MorphoSys AG, a biopharmaceutical company, since March 2020, a position he will retire from at the end of 2022. Prior to that Dr. Peters
served as its Chief Development Officer and member of its management board since March 2017. Prior to his time at MorphoSys, Dr. Peters
served as the Global Head of Clinical Development of the Biopharmaceuticals Business Unit at Sandoz International. From 2004 to 2015,
he served as Clinical Head and Site Head for Basel and East Hanover in the Department of Oncology Translational Medicine at Novartis.
Dr. Peters has also held teaching appointments in Internal Medicine and Biochemistry at the University of Mainz, Germany, served as Research
Scientist at the Amgen Research Institute in Toronto, Canada, as Director of Cancer Research at Merck KGaA and as Medical Director at
Micromet AG. Dr. Peters is a member of the Board of Directors of Tango Therapeutics, Inc. (NASDAQ: TNGX). Dr. Peters received his Doctor
of Medicine from the Freie Universität Berlin, Germany, and was trained at the Universities of Padova, Italy, and Bochum and Berlin,
Germany. After scientific work at different universities he habilitated in Internal Medicine at the University of Mainz, Germany. The
Board believes Dr. Peters’ extensive knowledge of the biotechnology industry makes him qualified to serve on the Company’s
Board.
Dr. Peters will be compensated for his service as a non-employee director
pursuant to the Company’s Non-Employee Director Compensation Policy. As a non-employee director, Dr.
Peters is entitled to an initial option to purchase 19,200 shares of the Company’s common stock and is also entitled to receive
an annual cash retainer of $40,000 and additional annual stock option awards, subject to his continued service on the Board.
The Company also entered into an indemnification agreement with Dr.
Peters in connection with his appointment to the Board, which is in substantially the same form as that entered into with the other directors
of the Company. There are no other arrangements or understandings between Dr. Peters and any other persons pursuant to which he was selected
as a director, and Dr. Peters has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item
404(a) of Regulation S-K.
Item 7.01 Regulation FD Disclosure
On December 9, 2022, the Board appointed Katia Schlienger as Chief
Medical Officer, effective January 1, 2023.
Dr. Schlienger has served as the Company’s Executive Vice President,
Clinical Research and Development since July 2022. Prior to that, Dr. Schlienger served as Senior Vice President, Head of Immuno-Oncology
Clinical Research and Development from January 2021 to June 2022. She previously worked at Merck & Co., for 14 years, serving in roles
of increasing responsibility across early and late-stage clinical development in oncology and vaccines. She received an M.D. from the
School of Medicine Lariboisiere Saint-Louis in Paris, France and a Ph.D. in Microbiology/Virology from Paris Diderot University.
On December 15, 2022, the Company issued a press release announcing
the appointments of Dr. Peters to the Board and Dr. Schlienger as the Chief Medical Officer. A copy of this press release is furnished
as Exhibit 99.1 to this report on Form 8-K.
The information in this Item 7.01 and Exhibit 99.1 attached hereto
is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934
(the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference
in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Exhibits
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: December 15, 2022
|
HOOKIPA Pharma, Inc.
|
|
|
|
|
|
By: |
/s/ Joern Aldag |
|
|
Joern Aldag |
|
|
Chief Executive Officer
(Principal Executive Officer) |
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Aug 2024 to Sep 2024
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Sep 2023 to Sep 2024